Role of Adipsin in the Mechanism of Glucose Intolerance by Statin Therapy
Not Applicable
Completed
- Conditions
- Health Condition 1: null- Newly diagnosed patients of dyslipidimia
- Registration Number
- CTRI/2017/11/010341
- Lead Sponsor
- Dr Jahnavi Maini
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 55
Inclusion Criteria
Treatment naive dyslipidemic patients (Low-density lipoprotein >=100mg/dl) or patients with ASCVD having dyslipidemia requiring statin therapy.
Exclusion Criteria
1.Patient with comorbid Type 1 and Type 2 Diabetes Mellitus.
2.Patients prescribed lipid lowering agents other than statins.
3.Any known history of condition(s) which may cause secondary dyslipidemia (e.g. nephrotic syndrome, glycogen storage disease etc.).
4.Any history of condition(s) which may affect euglycemia (pancreatic impairment or disease).
5.History of previous or current muscular or neuromuscular disease.
6.History of drugs which impair lipid profile or glycemic parameters.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To estimate and compare the change in serum adipsin levels in dyslipidemic patients from baseline with that of serum adipsin levels after 12 weeks of statin therapyTimepoint: 12 weeks
- Secondary Outcome Measures
Name Time Method 2.To study the correlation of serum adipsin levels with serum insulin & HbA1c levels following 12 weeks of statin therapyTimepoint: 12 weeks;To estimation and comparison of serum levels of adipsin (mean ± SD) in statin treatment group and NHVTimepoint: baseline